Prelude Therapeutics (PRLD) Operating Expenses (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Operating Expenses data on file, last reported at $18.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 45.8% year-over-year to $18.8 million; the trailing twelve-month figure through Mar 2026 stood at $100.9 million (down 31.38% YoY), and the FY2025 full-year result was $116.7 million, down 20.45% from the prior year.
• Operating Expenses slipped to $18.8 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $37.8 million in Q4 2024 to a low of $18.8 million in Q1 2026.
• A 5-year average of $31.6 million and a median of $32.4 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 37.88% in 2022 and slumped 45.8% in 2026, its largest moves.
• Tracing PRLD's Operating Expenses over 5 years: stood at $33.4 million in 2022, then increased by 11.96% to $37.4 million in 2023, then advanced by 1.21% to $37.8 million in 2024, then plunged by 39.24% to $23.0 million in 2025, then declined by 18.41% to $18.8 million in 2026.
• Business Quant data shows PRLD's Operating Expenses at $18.8 million in Q1 2026, $23.0 million in Q4 2025, and $26.9 million in Q3 2025.